Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients

J. Halámková, L. Bohovicová, L. Pehalová, R. Goněc, T. Staněk, T. Kazda, L. Mouková, DA. Krákorová, Š. Kozáková, M. Svoboda, R. Demlová, I. Kiss

. 2022 ; 14 (7) : . [pub] 20220327

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22017516

Grant support
MZ ČR - RVO (MOÚ, 00209805), BBMRI-CZ LM2018125, NU21-09-00558, RI CZECRIN LM2018128 Ministry of Health of the Czech republic

An increasing number of studies has brought evidence of the protective role of statin use against different types of cancer. However, data on their association with second primary malignancies (SPMs) are lacking. The purpose of this study was to determine the role of hypolipidemic treatment in the prevention of second primary cancer in colorectal cancer (CRC) survivors. We conducted a retrospective single-institution study of 1401 patients with newly diagnosed colorectal cancer from January 2003 to December 2016, with follow-up until December 2020. An SPM was detected in 301 patients (21%), and the incidence was significantly lower in patients with statin medication. However, stratification by cancer types revealed an increased incidence of bladder and gastric cancer in hypolipidemic users. A Kaplan-Meier analysis of early-stage CRC survivors with an SPM showed a significant survival benefit in patients without a history of hypolipidemic treatment. Despite the protective role of statins on overall second cancer incidence, these data indicate that CRC survivors treated with hypolipidemic drugs should be screened more cautiously for SPMs, especially for gastric and bladder cancer.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017516
003      
CZ-PrNML
005      
20240206090717.0
007      
ta
008      
220718s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers14071699 $2 doi
035    __
$a (PubMed)35406471
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Halámková, Jana $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $u Department of Medical Ethics, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
245    10
$a Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients / $c J. Halámková, L. Bohovicová, L. Pehalová, R. Goněc, T. Staněk, T. Kazda, L. Mouková, DA. Krákorová, Š. Kozáková, M. Svoboda, R. Demlová, I. Kiss
520    9_
$a An increasing number of studies has brought evidence of the protective role of statin use against different types of cancer. However, data on their association with second primary malignancies (SPMs) are lacking. The purpose of this study was to determine the role of hypolipidemic treatment in the prevention of second primary cancer in colorectal cancer (CRC) survivors. We conducted a retrospective single-institution study of 1401 patients with newly diagnosed colorectal cancer from January 2003 to December 2016, with follow-up until December 2020. An SPM was detected in 301 patients (21%), and the incidence was significantly lower in patients with statin medication. However, stratification by cancer types revealed an increased incidence of bladder and gastric cancer in hypolipidemic users. A Kaplan-Meier analysis of early-stage CRC survivors with an SPM showed a significant survival benefit in patients without a history of hypolipidemic treatment. Despite the protective role of statins on overall second cancer incidence, these data indicate that CRC survivors treated with hypolipidemic drugs should be screened more cautiously for SPMs, especially for gastric and bladder cancer.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bohovicová, Lucia $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Pehalová, Lucie $u Institute of Health Information and Statistics of the Czech Republic, 128 01 Prague, Czech Republic $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Goněc, Roman $u Department of Pharmacy, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
700    1_
$a Staněk, Teodor $u Department of Surgical Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic $u Department of Surgical Oncology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Kazda, Tomáš $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $1 https://orcid.org/0000000172888975
700    1_
$a Mouková, Lucie $u Department of Surgical Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
700    1_
$a Adámková Krákorová, Dagmar $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic $7 xx0084127
700    1_
$a Kozáková, Šárka $u Department of Pharmacy, University Hospital Brno, 625 00 Brno, Czech Republic $u Department of Pharmacology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Svoboda, Marek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Demlová, Regina $u Department of Pharmacology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $u Clinical Trial Unit, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
700    1_
$a Kiss, Igor $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 14, č. 7 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35406471 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220718 $b ABA008
991    __
$a 20240206090715 $b ABA008
999    __
$a ind $b bmc $g 1816626 $s 1168758
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c 7 $e 20220327 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a MZ ČR - RVO (MOÚ, 00209805), BBMRI-CZ LM2018125, NU21-09-00558, RI CZECRIN LM2018128 $p Ministry of Health of the Czech republic
LZP    __
$a Pubmed-20220718

Find record

Citation metrics

Archiving options